Kalaris Therapeutics (KLRS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Kalaris Therapeutics (KLRS) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.00 of bullish evidence against -0.37 bearish.

Kalaris Therapeutics last closed at $2.56, -3.76% on the session.

Against the IVW growth benchmark the position is -3.60% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

18 graded predictions for KLRS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Kalaris Therapeutics in the 14th percentile on return on equity, where 100 is best.

Kalaris Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $63.32M.

StockMap tracks Kalaris Therapeutics as the 300th largest of the 377 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 198 Moderate Underperform, 166 Neutral and 13 Strong Underperform.

On that composite Kalaris Therapeutics ranks 316th of 377 in the group, against a group median of -0.21.